<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02086656</url>
  </required_header>
  <id_info>
    <org_study_id>COI-B</org_study_id>
    <nct_id>NCT02086656</nct_id>
  </id_info>
  <brief_title>PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES</brief_title>
  <acronym>COI-B</acronym>
  <official_title>PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Capecitabine, oxaliplatin, irinotecan and bevacizumab as perioperative strategy of borderline&#xD;
      and/or high risk resectable colorectal cancer liver metastases&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies demonstrated a significant association between tumor regression grade of&#xD;
      hepatic colorectal metastases (TRG1: complete pathological response; TRG2: major pathological&#xD;
      response; TRG3: partial pathological response; versus TRG4-5 no pathological response) and&#xD;
      outcome in terms of survival after neoadjuvant treatment. In particular, retrospective data&#xD;
      showed an association between oxaliplatin-based chemotherapy and improvement of grade and&#xD;
      percentage of tumor regression; moreover, the addition of Bevacizumab seems to improve TRG&#xD;
      over chemotherapy alone, conferring also a protection against liver damage due to&#xD;
      chemotherapy-induced sinusoidal obstruction syndrome.&#xD;
&#xD;
      This is the rationale that induced us to carry out an evaluation and feasibility assessment&#xD;
      of a perioperative approach with COI-B regimen in patients affected by high risk or&#xD;
      borderline resectable colorectal liver metastases, with or without previous resection of&#xD;
      primary tumor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2013</start_date>
  <completion_date type="Actual">March 30, 2017</completion_date>
  <primary_completion_date type="Actual">March 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological response rate</measure>
    <time_frame>Assessed at the time of surgery of liver metastases (between weeks 17-20 from enrollment)</time_frame>
    <description>Primary:&#xD;
- To evaluate the activity of the regimen with regards to major/complete pathological response. Major/complete pathological response is measured by pathologist in terms of tumor regression grade (TRG) as described by Rubbia-Brandt L, Annals of Oncology 2007 (percentage of vial residual cells 0-10%).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RECIST Response rate</measure>
    <time_frame>Available at week 9 after enrollment</time_frame>
    <description>- Response rate according to RECIST vers. 1.1 criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Colorectal Cancer Liver Metastases</condition>
  <arm_group>
    <arm_group_label>open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm, open label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine, oxaliplatin, irinotecan and bevacizumab</intervention_name>
    <description>perioperative COI-B</description>
    <arm_group_label>open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Histological diagnosis of colorectal adenocarcinoma.&#xD;
&#xD;
          -  Liver-limited metastases or metastases mainly (â‰¥80% total disease burden) limited to&#xD;
             the liver with extrahepatic disease judged resectable concomitantly or sequentially.&#xD;
             Primary tumor may be resected or not, but patient must not be symptomatic for T.&#xD;
&#xD;
          -  Previous adjuvant therapy is allowed if it had been terminated for at least 6 months.&#xD;
&#xD;
          -  Previous first line treatment (irinotecan or oxaliplatin containing regimen) with&#xD;
             stable or partial response after no more than 3 months of treatment&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Performance Status (ECOG &lt;2)&#xD;
&#xD;
          -  Adequate organ function including the following:&#xD;
&#xD;
          -  Adequate bone marrow reserve: WBC count &gt;3.0x109/L, absolute neutrophil count&#xD;
             &gt;1.5x109/L, platelet count &gt;100x109/L, and hemoglobin &gt;10 g/dL .&#xD;
&#xD;
          -  Hepatic: bilirubin &lt; 1.5 times the ULN, alkaline phosphatase, aspartate transaminase,&#xD;
             and alanine transaminase &lt; 2.5 xULN&#xD;
&#xD;
          -  Renal : serum creatinin &lt;2.0xULN&#xD;
&#xD;
          -  Patients compliance and geographic proximity that allows for adequate follow-up&#xD;
&#xD;
          -  Patients must sign an informed consent document (ICD)&#xD;
&#xD;
          -  Male and female patients with reproductive potential must use an approved&#xD;
             contraceptive method.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumor involvement of liver &gt; 75%&#xD;
&#xD;
          -  Chance of a liver remnant after surgery &lt; 25%&#xD;
&#xD;
          -  Eligibility for concurrent radiotherapeutic treatment&#xD;
&#xD;
          -  Disease progression during first line chemotherapy with FOLFOX, XELOX, FOLFIRI or&#xD;
             XELIRI plus bevacizumab&#xD;
&#xD;
          -  Previous treatment with more than 3 months of FOLFOX or FOLFIRI&#xD;
&#xD;
          -  Previous therapy with bevacizumab or cetuximab or panitumumab&#xD;
&#xD;
          -  Administration of other experimental drugs during the study.&#xD;
&#xD;
          -  Body Mass Index &gt; 35&#xD;
&#xD;
          -  Brain metastases.&#xD;
&#xD;
          -  Pregnancy and breast-feeding.&#xD;
&#xD;
          -  Serious or uncontrolled medical pathologies or active infections that would jeopardize&#xD;
             the possibility of receiving the investigated treatment. Disorders that could&#xD;
             influence the absorption of capecitabine (e.g. malabsorption), intestinal occlusion,&#xD;
             Crohn's disease or ulcerative colitis.&#xD;
&#xD;
          -  Psychiatric disorders, neurologic disease or other conditions that would make it&#xD;
             impossible to comply with the protocol procedures. Peripheral neuropathy not related&#xD;
             to oxaliplatin previous administration.&#xD;
&#xD;
          -  Previous dangerous life threatening toxicities from fluoropyrimidine.&#xD;
&#xD;
          -  Positive anamnesis with regard to other neoplastic diseases except for the ones that&#xD;
             have been cured for more than 5 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filippo de Braud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale Tumori</name>
      <address>
        <city>Milan</city>
        <state>Mi</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 20, 2013</study_first_submitted>
  <study_first_submitted_qc>March 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2014</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</investigator_affiliation>
    <investigator_full_name>Filippo Pietrantonio, M.D.</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>liver metastases</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>perioperative treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

